|
|
Antibody derivatives for the detection of human glutamatecarboxypeptidase II
Bělousová, Nikola ; Bařinka, Cyril (advisor) ; Pavlíček, Jiří (referee)
Prostate cancer is one of the most common human malignancies and, consequently it is critical to develop appropriate diagnostic and therapeutic tools. Glutamate carboxypeptidase II (GCPII) is currently being considered one of the most important prostate cancer markers due to its tissue- specific expression. Whereas in healthy prostatic tissue the expression levels of GCPII are low, the transformation into the tumor is associated with the substantial increase of GCPII expression, with the highest levels observed in androgen-independent metastatic tumors. GCPII is thus considered a promising marker for early phase as well as advanced metastatic stages of prostate cancer. Current research is focused on the development of highly sensitive and specific reagents that allow detection of small amounts of GCPII, for example in early stages of cancer. Antibody derivatives are promising molecules for this purpose because they have high affinity and specificity and minimum negative side effects. Protein engineering is a prefered approach for preparation of various antibody molecules that differ in size, binding properties, stability, solubility, and production means. Different types of derivatives are being developed for medical needs such as in vitro diagnosis, therapy, and in vivo imagingSmall molecular...
|
|
|
Antibody derivatives for the detection of human glutamatecarboxypeptidase II
Bělousová, Nikola ; Bařinka, Cyril (advisor) ; Pavlíček, Jiří (referee)
Prostate cancer is one of the most common human malignancies and, consequently it is critical to develop appropriate diagnostic and therapeutic tools. Glutamate carboxypeptidase II (GCPII) is currently being considered one of the most important prostate cancer markers due to its tissue- specific expression. Whereas in healthy prostatic tissue the expression levels of GCPII are low, the transformation into the tumor is associated with the substantial increase of GCPII expression, with the highest levels observed in androgen-independent metastatic tumors. GCPII is thus considered a promising marker for early phase as well as advanced metastatic stages of prostate cancer. Current research is focused on the development of highly sensitive and specific reagents that allow detection of small amounts of GCPII, for example in early stages of cancer. Antibody derivatives are promising molecules for this purpose because they have high affinity and specificity and minimum negative side effects. Protein engineering is a prefered approach for preparation of various antibody molecules that differ in size, binding properties, stability, solubility, and production means. Different types of derivatives are being developed for medical needs such as in vitro diagnosis, therapy, and in vivo imagingSmall molecular...
|
|
|
Antibody derivatives for the detection of human glutamate carboxypeptidase II
Bělousová, Nikola ; Bařinka, Cyril (advisor) ; Černý, Jan (referee)
Prostate cancer is the most common neoplasia in men. The therapy of progressed tumor is usually not efficient and early diagnosis is therefore crucial for successful treatment. Glutamate carboxypeptidase II (GCPII) is an established marker for prostate cancer imaging and therapy as the neoplastic transformation of prostate tissue is accompanied by the substantial increase of GCPII expression levels. Currently used GCPII-specific diagnostic and therapeutic reagents can be broadly categorized as small- molecule ligands or macromolecules. Antibodies are preferred macromolecules used in clinic. At the same time, however, protein engineering is regularly applied to modify natural antibodies to enhance their utility in biomedicine applications. This thesis summarizes the current knowledge about the GCPII structure and function and its role in diagnosis and therapy of prostate carcinoma. Powered by TCPDF (www.tcpdf.org)
|
guest ::
